company background image
KURN

Kuros Biosciences SWX:KURN Stock Report

Last Price

CHF2.15

Market Cap

CHF78.6m

7D

-1.4%

1Y

22.9%

Updated

22 Sep, 2023

Data

Company Financials

KURN Stock Overview

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally.

KURN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Kuros Biosciences AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kuros Biosciences
Historical stock prices
Current Share PriceCHF2.15
52 Week HighCHF2.86
52 Week LowCHF1.11
Beta0.95
1 Month Change13.16%
3 Month Change66.67%
1 Year Change22.86%
3 Year Change-14.00%
5 Year Change-61.61%
Change since IPO-92.83%

Recent News & Updates

We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Sep 17
We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues

Jun 28
Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues

Recent updates

We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Sep 17
We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues

Jun 28
Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues

Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation

May 03
Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation

Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Jun 11
Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

Apr 12
Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years

Mar 02
Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years

What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

Nov 17
What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

Shareholder Returns

KURNCH BiotechsCH Market
7D-1.4%-0.3%-1.5%
1Y22.9%-40.6%7.5%

Return vs Industry: KURN exceeded the Swiss Biotechs industry which returned -41.6% over the past year.

Return vs Market: KURN exceeded the Swiss Market which returned 6.8% over the past year.

Price Volatility

Is KURN's price volatile compared to industry and market?
KURN volatility
KURN Average Weekly Movement10.6%
Biotechs Industry Average Movement7.0%
Market Average Movement3.2%
10% most volatile stocks in CH Market7.2%
10% least volatile stocks in CH Market1.6%

Stable Share Price: KURN is more volatile than 90% of Swiss stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: KURN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
201673Joost de Bruijnhttps://www.kuros.ch

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company’s orthobiologics pipeline products include MagnetOs Granules, MagnetOs Putty, MagnetOs Easypack Putty, and MagnetOs Flex Matrix in EU and US for the treatment of orthopedics, spinal, and dental problems.

Kuros Biosciences AG Fundamentals Summary

How do Kuros Biosciences's earnings and revenue compare to its market cap?
KURN fundamental statistics
Market CapCHF78.57m
Earnings (TTM)-CHF15.95m
Revenue (TTM)CHF20.43m

3.8x

P/S Ratio

-4.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KURN income statement (TTM)
RevenueCHF20.43m
Cost of RevenueCHF12.44m
Gross ProfitCHF7.99m
Other ExpensesCHF23.94m
Earnings-CHF15.95m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.44
Gross Margin39.11%
Net Profit Margin-78.07%
Debt/Equity Ratio0%

How did KURN perform over the long term?

See historical performance and comparison